Evidence
Trends Mol Med. 2024 Apr 10:S1471-4914(24)00063-7. doi: 10.1016/j.molmed.2024.03.008. Online ahead of print.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of pancreatic cancer, known for its challenging diagnosis and limited treatment options. The focus on metabolic reprogramming as a key factor in tumor initiation, progression, and therapy resistance has gained prominence. In this review we focus on the impact of metabolic changes on the interplay among stromal, immune, and tumor cells, as glutamine and branched-chain amino acids (BCAAs) emerge as pivotal players in modulating immune cell functions and tumor growth. We also discuss ongoing clinical trials that explore metabolic modulation for PDAC, targeting mitochondrial metabolism, asparagine and glutamine addiction, and autophagy inhibition. Overcoming challenges in understanding nutrient effects on immune-stromal-tumor interactions holds promise for innovative therapeutic strategies.
PMID:38604929 | DOI:10.1016/j.molmed.2024.03.008
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Exploiting pancreatic cancer metabolism: challenges and opportunities
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Exploiting pancreatic cancer metabolism: challenges and opportunities
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Exploiting pancreatic cancer metabolism: challenges and opportunities
🌐 365 Days
VR Related Evidence Matrix
